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Abstract To describe a coronary computed tomography
angiography (CCTA)-adapted Leaman score (CT-LeSc) as
a tool to quantify total coronary atherosclerotic burden with
information regarding localization, type of plaque and
degree of stenosis and to identify clinical predictors of a
high coronary atherosclerotic burden as assessed by the
CT-LeSc. Single center prospective registry including a
total of 772 consecutive patients undergoing CCTA (Dual-
source CT) from April 2011 to March 2012. For the pur-
pose of this study, 581 stable patients referred for suspected
coronary artery disease (CAD) without previous myocar-
dial infarction or revascularization procedures were inclu-
ded. Pre-test CAD probability was determined using both
the Diamond–Forrester extended CAD consortium method
(DF-CAD consortium model) and the Morise score. Car-
diovascular risk was assessed with the HeartScore. The cut-
off for the 3rd tercile (CT-LeSc C8.3) was used to define a
population with a high coronary atherosclerotic burden.
The median CT-LeSc in this population (n = 581, 8,136
coronary segments evaluated; mean age 57.6 ± 11.1;
55.8 % males; 14.6 % with diabetes) was 2.2 (IQR 0–6.8).
In patients with CAD (n = 341), the median CT-LeSc was
5.8 (IQR 3.2–9.6). Among patients with nonobstructive
CAD, most were classified in the lowest terciles (T1,
43.0 %; T2, 36.1 %), but 20.9 % were in the highest tercile
(T3). The majority of the patients with obstructive CAD
were classified in T3 (78.2 %), but 21.8 % had a CT-LeSc
in lower terciles (T1 or T2). The independent predictors of
a high CT-LeSc were: Male sex (OR 1.73; 95 % CI
1.04–2.90) diabetes (OR 2.91; 95 % CI 1.61–5.23),
hypertension (OR 2.54; 95 % CI 1.40–4.63), Morise score
C16 (OR 1.97; 95 % CI 1.06–3.67) and HeartScore C5
(OR 2.42; 95 % CI 1.41–4.14). We described a cardiac CT
adapted Leaman score as a tool to quantify total (obstruc-
tive and nonobstructive) coronary atherosclerotic burden,
reflecting the comprehensive information about localiza-
tion, degree of stenosis and type of plaque provided by
CCTA. Male sex, hypertension, diabetes, a HeartScore
C5 % and a Morise score C16 were associated with a high
coronary atherosclerotic burden, as assessed by the CT-
LeSc. About one fifth of the patients with nonobstructive
CAD had a CT-LeSc in the highest tercile, and this could
potentially lead to a reclassification of the risk profile of
this subset of patients identified by CCTA, once the
prognostic value of the CT-LeSc is validated.
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Introduction
Coronary atherosclerosis is the leading cause of mortality
and it is expected to remain the most important disease in
the upcoming years [1]. Frequently, the first manifestation
of coronary disease is an acute coronary syndrome (ACS),
and many patients were previously asymptomatic [2]. An
early detection of coronary disease is of utmost relevance
and a non-invasive diagnostic test is desirable.
In the recent years, coronary computed tomography
angiography (CCTA) has become widely available and
adopted. The main reason for this is the high predictive
accuracy of detection of obstructive coronary artery disease
(CAD) compared to conventional invasive coronary angi-
ography [3, 4]. In addition, CCTA allows also the identi-
fication of nonobstructive CAD and in this way it can
provide a noninvasive quantification of the total coronary
atherosclerotic burden. Since the percentage of patients
with nonobstructive CAD is very high, there is a need for
tools to stratify cardiovascular risk by the degree of plaque
burden [5]. The information regarding the localization,
severity and composition of coronary plaques identified
with CCTA can be collected in scores to reflect the total
coronary plaque burden, and some have been already
developed and validated [6].
Conventional cardiovascular (CV) risk factors relate to
the risk of subsequent CV events and they can be combined
in tools as it has been done in the Heart Score [7]. Not-
withstanding these observations, accurate prediction of
major coronary events on the individual patient level, as
opposed to population based studies, remains challenging.
Therefore the aim of this study is two folded: (1) To
describe a CCTA-adapted Leaman score (CT-LeSc) as a
tool to quantify total coronary atherosclerotic burden
including information regarding localization, type of pla-
que and degree of stenosis and; (2) To identify clinical
predictors of a high coronary atherosclerotic burden as
assessed by CT-LeSc in a population of stable patients
referred for CCTA for suspected CAD.
Methods
Population
Single center prospective registry including a total of 772
consecutive patients undergoing CCTA (with Dual source
CT) from April 2011 to March 2012. Patients were excluded
if: (1) previous myocardial infarction and/or revasculariza-
tion procedures (n = 70); (2) referred for Cardiac CT for
other indications than the evaluation of possible CAD (car-
diac CT for atrial fibrillation ablation or transcatheter aortic
valvular implantation procedures; n = 88); (3) referred for
suspected ACS (n = 24); (4) with atrial fibrillation or other
significant arrhythmias during scan acquisition that com-
promised image quality (n = 9). This resulted in a 24.7 % of
the total population being excluded.
For the purpose of this study, 581 stable patients refer-
red for suspected CAD were included in the context of: (1)
Previous equivocal or inconclusive stress tests or discor-
dant with the clinical evaluation (n = 417; 71.8 %); (2)
Cardiac CT as 1st line investigation of possible CAD
(n = 136; 23.4 %); (3) Preoperative CAD assessment prior
to noncoronary valvular or aortic surgery (n = 17; 2.9 %);
(4) Evaluation of possible CAD in cardiomyopathies
(DCM or HCM; n = 11; 1.9 %; Fig. 1: Patient selection
and study design).
The study was approved by the local ethics committee
and all patients gave a written informed consent.
A detailed medical history with a risk factors question-
naire was obtained from the patients to assess for the pres-
ence of: (1) Diabetes mellitus (defined as a fasting glucose
level of C7 mmol/l or the need for insulin or oral hypogly-
cemic agents) [8]; (2) Dyslipidemia (defined as a total cho-
lesterol level C5 mmol/l or treatment with lipid-lowering
drugs) [9]; (3) Hypertension (defined as blood pressure
C140/90 mm Hg or the use of antihypertensive medication)
[10]; (4) Obesity (body mass index C30 kg/m2); (5) positive
family history of premature CAD (defined as the presence of
CAD in first-degree relatives younger than 55 [male] or 65
[female] years of age) [11]; (6) smoking (defined as previous
[less\1 year] or current smoker.
Pre-test probability of CAD was determined using both
the Diamond and Forrester extended CAD consortium
method (DF-CAD consortium model) [12] and the Morise
score [13]. The cardiovascular risk was assessed with the
HeartScore [7]. As the CAD probability and CV risk of our
population was shifted to lower probability and risk, the
cut-offs used were: (1) for DF-CAD consortium model
categories C30–70 and C70 % were gathered in a Inter-
mediate to High (C30 %) probability group.
For the Morise, the population was divided in terciles,
and for the HeartScore the established high risk cut-off of
C5 % was used.
Scan protocol and image reconstruction
All scans were performed with a dual-source scanner
(Somatom Definition, Siemens Medical, Germany), with
the patient in dorsal decubitus and in deep inspiration
breath-hold. Sublingual nitroglycerin was administered to
all patients except when contraindicated and intravenous
metoprolol (5 mg, with a titration dose up to 20 mg) was
administered in patients with heart rate [65 beats/min.
During the scan acquisition, a bolus of iodinated con-
trast (Visipaque, GE Healthcare, USA) was injected at a
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6 ml/s infusion rate, followed by a 50-ml saline flush. The
dose of contrast was calculated according to the following
formula: (acquisition time ?6 s delay) 9 flow (6 ml/s).
Contrast timing was performed to optimize uniform con-
trast enhancement of the coronary arteries.
Dose reduction strategies—including electrocardiogram-
gated tube current modulation, reduced tube voltage,
and prospective axial triggering—were used whenever fea-
sible. Mean estimated radiation dose was 4.6 ± 3.7 mSv,
contrast dose was 98.9 ± 14.4 ml and heart rate was
65.6 ± 10.6 bpm.
Transaxial images were reconstructed with a temporal
resolution of 83 ms and slice thickness of 0.75 mm with
0.4 mm increments.
Post-processing was carried out using Circulation
software, with multiplanar reconstructions, maximum
intensity projection and volume rendering technique.
Coronary artery analysis
All scans were analyzed in the same session by both a car-
diologist and a radiologist with Level III-equivalent expe-
rience. The Society of Cardiovascular Computed
Tomography recommended classification was used regard-
ing segmentation (16 segments), stenosis severity (\25,
25–49, 50–69, 70–99, 100 %) and plaque composition
(calcified, non calcified, mixed plaque) [14].
In each coronary artery segment, coronary atherosclerosis
was defined as a tissue structure[1 mm2 that existed either
within the coronary artery lumen or adjacent to the coronary
artery lumen that could be discriminated from surrounding
pericardial tissue, epicardial fat, or the vessel lumen itself
[6]. Coronary atherosclerotic lesions were quantified for
stenosis by visual estimation. Percent obstruction of coro-
nary artery lumen was based on a comparison of the luminal
diameter of the segment exhibiting obstruction to the luminal
diameter of the most normal-appearing site immediately
proximal to the plaque.
CCTA adapted Leaman score (CT-LeSc)
For the CT adaptation of the LeSc, we used three sets of
weighting factors, all noninvasively provided by CCTA:
(1) localization of the coronary plaques as originally
described [15]. In this study, a modification was made to
account for balanced dominance. In cases of balanced
dominance, not taken in account in the original Leaman or
in the Syntax scores, we assumed an intermediate value
between right and left dominance which changed the val-
ues for the posterior descending and the proximal, mid and
Fig. 1 Patient selection and
study design. CAD coronary
artery disease, TAVI
transcatheter aortic valve
implantation, aFib atrial
fibrillation, MI myocardial
infarction, CABG coronary
artery bypass grafting, PCI
percutaneous coronary
intervention, ACS acute
coronary syndromes
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distal RCA segments as well as for the left main and
proximal and distal segments of the circumflex; (2) type of
plaque (i.e. noncalcified, calcified or mixed plaques). To
take in account the cardiac CT added information related to
plaque composition, an additional weighting factor of 1.5
was added to predominantly noncalcified of mixed plaques
and a factor of 1 to predominantly calcified plaques,
reflecting the assumption of less plaque vulnerability of the
later ones [16, 17]; (3) degree of stenosis (\50 C% ste-
nosis). In the presence of obstructive CAD (C50 % ste-
nosis), the score in each segment was multiplied by 1 and
for nonobstructive CAD it was multiplied by a factor of
0.615. This factor reflects the relative proportion in the
published hazard ratios for mortality in the large CON-
FIRM registry [5] for obstructive versus nonobstructive
CAD (2.6 vs 1.6 respectively) and it was assumed to reflect
the relative prognostic impact of nonobstructive CAD
(Table 1).
The CT-LeSc on a patient level was calculated as the
sum of the partial CT-LeSc of all evaluable coronary
segments. Two cases examples are shown in Fig. 2.
Statistical analysis
Continuous variables are presented as mean ± SD or
medians (interquartile range) and categorical variables as
frequencies with percentages.
The non-parametric Mann–Whitney or Kruskal–Wallis
tests were used to compare continuous variables, and the Chi
square test to evaluate differences in frequencies. Differ-
ences were regarded significant when p \ 0.05 (two-tailed).
Since there are no previous validated cut-offs for the
presently described CCTA score, the population with CAD
was divided in terciles. A high CT-LeSc was defined with
the cut-off for the 3rd tercile (a score C8.3, n = 116;
34.8 % of the CAD population) and patients in this group
were compared with the remaining population.
Multivariate analyses (binary logistic regression model—
enter method) were performed to identify independent pre-
dictors of a high CT-LeSc using the demographic and clin-
ical variables presented in Table 2 that had a p value\0.2 at
univariate analyses. A second multivariable analyses was
performed to identify independent predictors among the
clinical scores of CAD probability (Diamond–Forrester
CAD consortium model and Morise score) and the CV risk
score HeartScore.
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was
used for all statistical analyses.
Results
In the final study population of 581 patients, 8,136 coronary
segments were evaluated. Segments \2 mm (n = 742;
9.1 %) or with suboptimal image quality related to artefacts
or severe calcification (n = 120; 1.5 %) were excluded.
Most of patients were male (55.8 %) and mean age was
57.6 ± 11.1, and 14.6 % were diabetics. This was predom-
inantly a population with low to intermediate CAD proba-
bility since 60.1 % had a DF-CAD consortium \30 and
87.6 % had a Morise score\16. A high cardiovascular risk,
as assessed by an HeartScore C5 %, was present in 25.5 % of
the patients. In this population, the median calcium score was
1 (IQR 0–93), 23.4 % had a calcium score (CaSc) C100 and
14.3 % had a CaSc C75th percentile. In the population with
CAD, the median CaSc was 64 (IQR 8–200; Table 2).
CT-LeSc
Overall (n = 581), the median CT-LeSc in this population
was 2.2 (IQR 0–6.8). In patients with CAD (n = 341), the
Table 1 CT-adapted Leaman Score (CT-LeSc) weighting factors
Segment Right
dominance
Left
dominance
Balanced
Coronary segments
RCA proximal 1 0 0.5
RCA mid 1 0 0.5
RCA distal 1 0 0.5
PDA 1 na 0.5
Left main 5 6 5.5
LAD proximal 3.5 3.5 3.5
LAD mid 2.5 2.5 2.5
LAD distal 1 1 1
1st diagonal 1 1 1
2nd diagonal 0.5 0.5 0.5
LCx proximal 1.5 2.5 2.0
1st obtuse marginal 1 1 1
LCx distal 0.5 1.5 1
2nd obtuse marginal 1 1 1
PDA from LCA na 1 na
PL branch from
LCA
na 0.5 0.5
PL branch
from RCA
0.5 na na
Intermediate branch 1 1 1
Stenosis severity
Obstructive CAD 1
Nonobstructive CAD 0.615
Plaque composition
Non-calcified or mixed 1.5
Calcified 1
RCA right coronary artery, PDA posterior descending artery, LAD left
anterior descending, LCx left circumflex, PL postero-lateral, CAD
coronary artery disease
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median CT-LeSc was 5.8 (IQR 3.2–9.6). Within this pop-
ulation the median CT-LeSc in patients with non-obstruc-
tive disease (n = 263) was 4.6 (IQR 2.9–7.7) and in
patients with obstructive disease (n = 78) it was 11.7 (IQR
8.7–14.4). The terciles in population with CAD were: T1
B3.7 (0.3–3.7); T2 (3.8–8.3); T3 C8.3 (8.3–24.1).
Regarding the distribution of patients with nonobstruc-
tive versus obstructive CAD across the CT-LeSc terciles,
most of the patients with nonobstructive CAD were in T1
(n = 113, 43.0 %) or T2 (n = 95, 36.1 %), but about one
fifth (n = 55, 20.9 %) were in the highest tercile (T3, CT-
LeSc C8.3). On the other hand, although most of the patients
with obstructive CAD were classified in T3, 21.8 % had a
CT-LeSc in lower terciles (T1, 2.6 %; T2, 19.2 %; Fig. 3).
The median CT-LeSc was significantly higher in males
and in the presence of diabetes and hypertension, as well as
in patients with a high cardiovascular risk assessed by an
HeartScore C5 %. The median CT-LeSc was also signifi-
cantly higher in patients with a CaSc C100 and CaSc
C75th percentile (Fig. 4: Median CT-LeSc in different
patient subgroups).
Univariate predictors
In the univariate analysis, a high CT-LeSc was associated
with older age (C60 years), diabetes and hypertension. The
percentage of male patients and patients with dyslipidemia
was also higher in the high CT-LeSc group, but not sta-
tistically significant. Patients in the high CT group had also
a higher pre-test CAD probability (DF-CAD consortium
C30 % and Morise score C16) as well as higher CV risk,
reflected in the significantly higher percentage of patients
with a HeartScore C5 %. Of note, some traditional risk
factor as obesity, smoking status and family history of
premature CAD were not differently distributed in the two
groups, and this was also the case for chest pain (Table 3).
Multivariate predictors
By multivariate analysis, the independent predictors of a
high CT-LeSc were: male sex; diabetes, hypertension,
Morise score C16 and HeartScore C5 (Table 4; Fig. 5). Of
note, regarding the modifiable risk factors, patients with
Fig. 2 Three cases examples of patients with nonobstructive CAD
stratified by different coronary atherosclerotic burden scores. In panel
A, a patient with a single lesion in the mid-RCA (weighting for
localization 9 type of plaque 9 stenosis severity = 1 9 1.5 9
0.615 = 0.92); In panel B, a patient with a single proximal LAD
lesion (CT-LeSc = 3.5 9 1 9 0.615 = 2.15). In panel C, a patient
with left dominance and 5 nonobstructive lesions with a total
CT-LeSc = LM (6 9 1.5 9 0.615) ? prox. LAD (3.5 9 1.5 9
0.615) ? mid-LAD (2.5 9 1 9 0.615) ? 1st Diag. (1 9 1 9 0.615) ?
1st OM (1 9 1 9 0.615) = 11.5. CAD coronary artery disease,
CT-LeSc CT Leaman score, SIS segment involvement score, SSS
segment stenosis score, LM left main, LAD left anterior descending,
LCx left circunflex, RCA right coronary artery, 1st Diag. first diagonal
branch, 1st OM first obtuse marginal branch
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diabetes had a threefold and patients with hypertension a
2.5-fold higher probability of having a high CT-LeSc.
A high HeartScore (C5 %) and a high Morise score
(C16) were associated respectively with a 2.5 and twofold
higher probability of having a high coronary atheroscle-
rotic burden, as assessed by the CT-LeSc.
Discussion
The main findings of this study are: (1) Calculation of a
cardiac CT adapted Leaman score as a tool to quantify total
(obstructive and nonobstructive) coronary atherosclerotic
burden, reflecting the comprehensive information about
localization, degree of stenosis and type of plaque provided
by CCTA is feasible; (2) There was a significant associa-
tion between the CT-LeSc and diabetes, a well recognized
subset of advanced coronary atherosclerotic burden. A high
CV risk (HeartScore) and a high CAD probability (Morise
score) were also both associated with nearly a 2–2.5 fold
higher probability of having a high coronary atheroscle-
rotic burden, as assessed by the CT-LeSc.
Although the exclusion of obstructive CAD remains
presently the main indication to refer a patient for CCTA,
this noninvasive diagnostic tool can also provide infor-
mation regarding the presence of nonobstructive plaques,
detecting CAD at earlier disease stages. Although on a per
lesion basis, vulnerability is positively associated with the
degree of stenosis, on a per patient level most of the acute
events come from nonobstructive lesions [18–20]. It is also
recognized that many of the nonstenotic lesions can have a
high plaque burden, underestimated by luminal angio-
grams, since they undergo expansive or positive outward
enlargement, and such remodeling is a potential surrogate
marker of plaque vulnerability [21]. In the multicenter
virtual histology intravascular ultrasound (VH-IVUS)
PROSPECT study [22], a large plaque burden, a small
lumen area and the presence of a thin cap fibroatheroma
were independent predictors of future nonculprit lesion
major adverse cardiac events (MACE). In this study,
lesions that led to MACE had a high plaque burden by
Table 2 Demographic, clinical and CCTA characteristics of the
study population
All patients (n = 581)
Demographic
Age 57.6 ± 11.1
Male sex 324 (55.8)
Risk factors
Obesity (BMI C30) 109 (18.8)
Diabetes 85 (14.6)
Hypertension 364 (62.7)
Dyslipidemia 360 (62.0)
Smoking 138 (23.8)
Family history of premature CAD 194 (33.4)
Chest pain
Asymptomatic 270 (46.5)
Noncardiac 169 (29.1)
Atypical 109 (18.8)
Typical 33 (5.7)
CAD probability
DF-CAD consortium C70 % 11 (1.9)
DF-CAD consortium 30–70 % 221 (38.0)
DF-CAD consortium \30 % 349 (60.1)
Morise score C16 72 (12.4)
Morise score 9–15 369 (63.5)
Morise score 0–8 140 (24.1)
CV risk
Heart score C5 % 148 (25.5)
Calcium score
Median 1 (0–93)
Median in patients with CAD 64 (8–200)
CaSc C100 136 (23.4)
CaSc C75th percentile 83 (14.3)
CCTA
Normal/no plaque 240 (41.3)
Nonobstructive CAD 263 (45.3)
Obstructive CAD 78 (13.4)
Technical data
Heart rate (bpm) 65.6 ± 10.6
Contrast dose (ml) 98.9 ± 14.4
Radiation dose (mSv) 4.6 ± 3.7
Values are mean ± SD, median (IQR) or n (%)
CAD coronary artery disease, BMI body mass index, DF-CAD con-
sortium Diamond–Forrester CAD consortium model, CV cardiovas-
cular, CCTA coronary computed tomography angiography, CaSc
calcium score, bpm beats per minute, mSv milisievert
Fig. 3 Distribution of the two subgroups of patients (nonobstructive
and obstructive CAD), according to CT-LeSc terciles (T1 ? T2 vs
T3). CAD coronary artery disease, T1 1st tercile, T2 2nd tercile, T3
3rd tercile
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IVUS, but were mild by baseline angiography (mean
diameter stenosis 32 %). The prognostic value of nonob-
structive CAD has also been recently reinforced from large
cardiac CT registries (CONFIRM) and meta-analysis [23].
In the large international multicenter CONFIRM regis-
try, all-cause mortality was significantly higher for patients
with nonobstructive CAD, as compared with patients
without coronary atherosclerosis. One notable finding in
this registry is the superimposed survival curves of non-
obstructive and 1 vessel obstructive CAD, reinforcing the
prognostic impact of nonobstructive coronary lesions [6].
Why a plaque burden CT score?
The main reason is because CAD represents a very heter-
ogeneous condition and there is a need to structure the
quantification of the plaque burden and to integrate the
most important information collected by CT and finally to
homogenize the reporting of CT findings.
There are already some CT scores developed and
prognostically validated namely the segment involvement
score (SIS) and the segment stenosis score (SSS), but they
only reflect some aspects of the coronary atherosclerotic
burden, the former only takes into account the number of
segments with plaque and the latter the degree of stenosis
[6]. The CT-LeSc reflects some of the aspects that are
partially included in the SIS (number of segments with
plaque) and the SSS (degree of stenosis), and combines
these two aspects, and also the localization, on a more
comprehensive score.
Why these three components?
Individually, localization of the plaque within the coronary
tree, the type of plaques and degree of stenosis are strong
predictors of future coronary events.
Since CCTA is able to reliably collect information on
these three aspects, a comprehensive score should be able
to integrate these components.
Fig. 4 Median CT-LeSc in different patient subgroups. DM diabetes mellitus, HTA hypertension, CA score calcium score, CT-LeSc CT Leaman
score
Table 3 Univariate analysis
CT LeSc
T1 ? 2
(\8.3)
CT
LeSc C
T3 (C8.3)
p
Age C60 126 (56.0) 79 (68.1) 0.031
Male sex 138 (61.3) 81 (69.8) 0.121
BMI C30 41 (18.3) 25 (22.1) 0.404
Diabetes 26 (11.6) 36 (31.0) \0.001
Hypertension 144 (64.0) 98 (84.5) \0.001
Dyslipidemia 146 (64.9) 87 (75.0) 0.057
Smoking 53 (23.6) 31 (26.7) 0.520
Family history of premature
CAD
77 (34.2) 37 (31.9) 0.666
Chest pain 106 (47.3) 59 (51.3) 0.487
DF-CAD consortium C30 % 66 (29.3) 64 (55.2) \0.001
Morise score C16 105 (46.7) 78 (67.2) \0.001
Heart score C5 29 (12.9) 24 (20.7) 0.060
Values are n (%); CAD coronary artery disease, BMI body mass
index, DF-CAD consortium-diamond–Forrester CAD consortium
model
Table 4 Multivariate analysis—independent predictors of a high CT-
LeSc (3rd tercile, score C8.3)
OR (95 % CI) p
Demographic and clinical variables
Age C60 1.370 0.819–2.291 0.230
Male sex 1.732 1.035–2.901 0.037
Diabetes 2.905 1.612–5.234 \0.001
Hypertension 2.543 1.395–4.634 0.002
Dyslipidemia 1.563 0.919–2.660 0.099
Clinical scores
Heart score C5 2.416 1.411–4.135 0.001
DF-CAD consortium C30 % 1.590 0.918–2.754 0.098
Morise C16 1.971 1.060–3.666 0.032
OR odds ratio, DF-CAD consortium Diamond–Forrester CAD con-
sortium model
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Regarding localization, the original Leaman score was
developed as a score to quantify obstructive coronary dis-
ease identified with invasive angiography [15]. In this
score, with the rational of relative blood supply to the left
ventricle, all coronary segments were given a weighting
factor, reflecting the relative contribution of blood flow to
the left ventricle of each vessel segment, taking also in
account the specific right or left dominance systems.
Recently, this score was used as the segment weighting
factor for the development of the syntax score [24] which
has been proven to have a strong prognostic value in dif-
ferent clinical scenarios [25, 26]. In our score, values were
also provided for balanced dominance, reflecting more
adequately the anatomical variants of the coronary tree.
Plaque composition has been found in both pathological
and clinical studies associated with cardiac events [22, 27].
CCTA has shown to be able to characterize plaque com-
position [28]. Thin cap fibroatheroma is the most common
pathological substrate of ACS and in CCTA these plaques
appear as noncalcified or mixed plaques [16]. In a recent
study by Maurovich-Horvat et al. [16], the frequency of a
napkin-ting sign, a CCTA feature of advanced lesions by
histology, was similar between noncalcified and mixed
plaques, which also reinforces our weighting factor in the
CT-LeSc for plaque composition that was the same
between these two types (a factor of 1.5), and different
from predominantly calcified plaques (a factor of 1).
Regarding the degree of stenosis, we assumed in our
scoring system a factor reflecting the proportion of the
hazard ratios for obstructive versus nonobstructive observed
in the recently large scale CONFIRM registry. By gathering
all the nonobstructive (\25, 25–49 %) and obstructive
(50–69, 70–99, 100 %) in the same risk categories, this
scoring system is expected to have a good intra and inter-
observer correlation, since the other two weighting factors
(localization and plaque calcification) have also an excellent
reproducibility and are usually described in CCTA
reporting.
Clinical implications
Many tools are already available to help stratifying patients
at risk of a CV event and some scores have been already
developed gathering the information provided by the dif-
ferent traditional risk factors, like the Framingham score or
the HeartScore. Notwithstanding these observations,
accurate prediction of major coronary events on the indi-
vidual patient level, as opposed to population based stud-
ies, remains challenging.
The clinical implications of a score that reflect the extent
of coronary atherosclerotic burden is related to the fact that
this way we can have a tool to quantify and compare this
burden, which is particularly useful when reporting a
CCTA of a patient without obstructive CAD, but in whom
the extent of nonobstructive CAD could lead to a reclas-
sification of his risk profile and thereby his cardiovascular
treatment.
Of note in our study is the fact that although the CT-
LeSc, by having the degree of stenosis in its composition,
tends to favour patients with obstructive CAD, we were
able to demonstrate that a significant percentage (20.9 %)
of patients with nonobstructive CAD had in fact a CT-LeSc
in the highest tercile (T3). Conversely, among patients with
obstructive CAD, about one fifth had a coronary
Fig. 5 Independent predictors
of a high CT-LeSc (score C8.3).
CT-LeSc CT Leaman score
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atherosclerotic burden, as assessed by the CT-LeSc, in
lower terciles.
The CT-LeSc, by having a weight related to the locali-
zation, it reflects not only the extent of CAD but also the
expected clinical consequences in case that the more
proximal lesions evolve to a significant stenosis or become
unstable and trigger a coronary event.
In our study, a high HeartScore and a high Morise score
were both associated with nearly a 2–2.5 fold higher prob-
ability of having a high coronary atherosclerotic burden, as
assessed by the CT-LeSc. This could be expected for the
HeartScore, as it was develop as a tool to predict cardio-
vascular risk. In the case of the Morise score, is was
developed and validated as a clinical tool to estimate the
probability of CAD, but it has also been linked to cardio-
vascular outcomes [29]. The Diamond–Forrester was not an
independent predictor of a high CT-LeSc and although we
used the recently calibrated CAD consortium model [12], is
has been developed and calibrated for obstructive CAD
identified with invasive angiography and doesn’t take in
account the cardiovascular risk factors in its composition.
Limitations
There are a number of limitations related to this report: (1)
This is a single center data with medium size cohort; (2) High
prevalence of low CAD probability/CV risk patients. The
population included in our study was mainly composed of
patients with low to intermediate CAD probability and CV
risk. Nevertheless, CAD was present in nearly 60 % of the
patients and this reflects the daily practice and the recom-
mendations that high CAD probability patients have not an
appropriate indication for CCTA [30]; (3) For the weighting
factor of plaque composition, we used a multiplication factor
of 1.5 for mixed and noncalcified plaques. Although this was
an arbitrary factor, this is in line with several CCTA prog-
nostic studies that demonstrated lower hazard ratios for
calcified plaques and reflects an assumption of less plaque
vulnerability of calcified plaques. (4) Lack of prognostic
validation: the aim of this study was to describe a CCTA
score to quantify total coronary atherosclerotic burden and to
identify its clinical predictors. Future studies will be needed
to provide a prognostic validation of this described CT-LeSc.
Conclusions
The calculation of the CCTA-adapted Leaman score as a
tool to quantify total (obstructive and nonobstructive)
coronary atherosclerotic burden, reflecting the compre-
hensive information about localization, degree of stenosis
and type of plaque provided by CCTA is feasible. There
was a significant association between the CT-LeSc and
some traditional demographic and clinical risk factors. In
face of this association, we expect this score to be a useful
tool to quantify the coronary atherosclerotic burden eval-
uated by CCTA and it is expected to convey prognostic
information, and this should be evaluated in future studies.
About one fifth of the patients with nonobstructive CAD
had a CT-LeSc in the highest tercile, which could poten-
tially lead to a reclassification of the risk profile of these
subset of patients identified by CCTA, once the prognostic
value of the CT-LeSc is validated.
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